Hyaluronic acid synthase mutants and their applications

By mutating key amino acid sites of hyaluronic acid synthase, the microbial fermentation production of hyaluronic acid with different molecular weights was regulated, solving the problem of difficulty in controlling the molecular weight of hyaluronic acid in existing technologies and realizing efficient industrial production.

CN117402848BActive Publication Date: 2026-11-17TSINGHUA UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311278864.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-28
Publication Date
2026-11-17
Estimated Expiration
2043-09-28

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively regulate the microbial fermentation production of hyaluronic acid of different molecular weights, especially high molecular weight hyaluronic acid, and the catalytic mechanism of hyaluronic acid synthase has not yet been fully elucidated.

Method used

By mutating key amino acid sites (positions 27, 28, 349, and 352) of hyaluronic acid synthase, especially by mutating them into positively or negatively charged amino acids, the microbial fermentation production of hyaluronic acid of different molecular weights can be regulated, and recombinant cells and engineered bacteria can be constructed.

Benefits of technology

Significant control over the molecular weight of hyaluronic acid produced by microbial fermentation was achieved, improving the production efficiency of high molecular weight hyaluronic acid and making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004477834920000101
    Figure BDA0004477834920000101
  • Figure BDA0004477834920000111
    Figure BDA0004477834920000111
  • Figure BDA0004477834920000131
    Figure BDA0004477834920000131
Patent Text Reader

Abstract

This invention discloses a hyaluronic acid synthase mutant, nucleic acid, vector, recombinant cells, engineered bacteria, and their applications. The hyaluronic acid synthase mutant comprises: a protein having a mutation at at least one of the amino acid positions 27, 28, 349, and 352 compared to the amino acid sequence shown in SEQ ID NO: 1, and possessing hyaluronic acid synthase activity; or a protein having at least 80% homology with the amino acid sequence of said protein and possessing hyaluronic acid synthase activity. Using the hyaluronic acid synthase mutant of this invention, microbial fermentation can be regulated to produce hyaluronic acid of different molecular weights. Based on the nucleic acid encoding the hyaluronic acid synthase mutant, different recombinant cells can be constructed, thereby obtaining engineered bacteria capable of producing hyaluronic acid of different molecular weights, suitable for industrial production applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a hyaluronic acid synthase mutant, nucleic acid, vector, recombinant cell and engineered bacteria and their applications. Background Technology

[0002] Hyaluronic acid (HA) is an acidic mucopolysaccharide with a linear structure that is widely found in humans and animals. It is composed of alternating monosaccharide units of D-glucuronic acid and N-acetylglucosamine (Weigel P, et al., Journal of Biological Chemistry, 1997, 272(22):13997-14000.). As an acidic mucopolysaccharide, HA has biocompatibility, bioavailability, and moisturizing properties, and has been widely used in the pharmaceutical, food, and cosmetic industries. HA of different molecular weights has different biological properties. High molecular weight HA (>1 MDa) is often used in clinical medicine and can be used for intra-articular injections and ophthalmic surgery; medium molecular weight HA (0.1-1 MDa) is often used in skin care and cosmetic products, with moisturizing and anti-aging effects; low molecular weight HA (<0.1 MDa) is often used in food and health products, and can promote cell metabolism.

[0003] With the rapid development of synthetic biology, hyaluronic acid (HA) synthesis has achieved a fully biological synthesis without animal-derived raw materials, with microbial fermentation being the main method for HA production. Currently, industrial-scale production uses *Streptococcus equi* fermentation to produce HA. A research group at Tsinghua University has developed a method using *Corynebacterium glutamicum* as a host to achieve high HA production, but the molecular weight still needs further improvement. Some researchers have attempted to regulate the molecular weight of HA at the enzyme level, but because the mechanism of hyaluronic acid synthase catalyzing HA synthesis and transport is not fully understood, there are few related reports in the literature.

[0004] The current research status, especially the technology of regulating microbial fermentation to produce HA of different molecular weights at the enzyme molecular level, still needs further investigation. Summary of the Invention

[0005] This invention aims to at least partially address one of the technical problems existing in the prior art. To this end, this invention provides a hyaluronic acid synthase mutant, nucleic acid, vector, recombinant cells, engineered bacteria, and their applications. Using the hyaluronic acid synthase mutant of this invention, the microbial fermentation production of HA of different molecular weights can be regulated. Based on the nucleic acid encoding this hyaluronic acid synthase mutant, different recombinant cells can be constructed, thereby obtaining engineered bacteria capable of producing HA of different molecular weights, suitable for industrial production applications.

[0006] It should be stated that this invention was completed based on the following work of the inventors:

[0007] To regulate the microbial fermentation production of HA of different molecular weights, the inventors conducted in-depth research on wild-type hyaluronic acid synthase. Through enzyme sequence alignment analysis and structural simulation, they identified key structural domains in the membrane-binding region of hyaluronic acid synthase, particularly amino acid sites 27, 28, 349, and 352, which may be related to the binding affinity of HA glycans to hyaluronic acid synthase. Therefore, the inventors hypothesize that mutations at these four amino acid sites could potentially regulate the microbial fermentation production of HA of different molecular weights, especially high molecular weight HA.

[0008] Given that HA carries a negative charge, the inventors mutated one or more of the four amino acid sites mentioned above to positively or negatively charged amino acids, and found that this could change the molecular weight of HA produced by fermentation. Further experiments demonstrated that mutating at least one of the amino acids at positions 27, 28, 349, and 352 of the wild-type hyaluronic acid synthase to a positively charged amino acid significantly increased the molecular weight of HA produced by biofermentation.

[0009] Therefore, in a first aspect, the present invention provides a hyaluronic acid synthase mutant. The hyaluronic acid synthase mutant comprises:

[0010] A protein having a mutation at at least one of the amino acid positions 27, 28, 349, and 352 compared to the amino acid sequence shown in SEQ ID NO: 1, and possessing hyaluronic acid synthase activity; or

[0011] A protein that has at least 80% homology to the amino acid sequence of the protein and has hyaluronic acid synthase activity.

[0012] The hyaluronic acid synthase mutant according to embodiments of the present invention can be used to regulate the microbial fermentation to produce HA of different molecular weights. Based on the nucleic acid encoding the hyaluronic acid synthase mutant, different recombinant cells can be constructed, thereby obtaining engineered bacteria that can produce HA of different molecular weights, which are suitable for industrial production applications.

[0013] In a second aspect, the present invention provides a nucleic acid. This nucleic acid encodes the aforementioned mutant. According to embodiments of the present invention, the nucleic acid can encode a hyaluronic acid synthase mutant capable of regulating microbial fermentation to produce HA of different molecular weights, as described in the first aspect of the invention.

[0014] In a third aspect, the present invention provides a vector carrying the aforementioned nucleic acid. The vector may include an optional control sequence operatively linked to the nucleic acid molecule. The control sequence is one or more control sequences that can direct the expression of the nucleic acid molecule in a host. The resulting vector can effectively express the hyaluronic acid synthase mutant of the first aspect of the present invention.

[0015] In a fourth aspect, the present invention provides a recombinant cell. The recombinant cell expresses the aforementioned hyaluronic acid synthase mutant; or carries the aforementioned nucleic acid or the aforementioned vector. Thus, according to embodiments of the present invention, the recombinant cell can efficiently express the hyaluronic acid synthase mutant of the first aspect of the present invention under suitable conditions, further resulting in engineered bacteria capable of producing HA of different molecular weights, suitable for industrial production applications.

[0016] In a fifth aspect, the present invention provides an engineered bacterium. The engineered bacterium comprises: the aforementioned hyaluronic acid synthase mutant, the aforementioned nucleic acid, or the aforementioned vector. According to embodiments of the present invention, the engineered bacterium can be used to produce HA of different molecular weights, suitable for industrial production applications.

[0017] In a sixth aspect, the present invention provides a method for obtaining hyaluronic acid. The method includes:

[0018] The aforementioned engineered bacteria were fermented to obtain hyaluronic acid.

[0019] Those skilled in the art will understand that the features and advantages described above for hyaluronic acid synthase mutants, nucleic acids, recombinant cells or engineered bacteria are also applicable to this method, and will not be repeated here.

[0020] In a seventh aspect, the present invention provides a method for increasing the molecular weight of hyaluronic acid produced by engineered bacteria. The method includes:

[0021] The nucleic acid molecule encoding the aforementioned hyaluronic acid synthase mutant was constructed into an expression vector to obtain a recombinant expression vector;

[0022] The recombinant expression vector was introduced into a host bacterium capable of expressing wild-type hyaluronic acid synthase to obtain engineered bacteria;

[0023] The engineered bacteria were fermented to obtain hyaluronic acid.

[0024] Those skilled in the art will understand that the features and advantages described above for hyaluronic acid synthase mutants, nucleic acids, recombinant cells, or engineered bacteria are also applicable to this method and will not be repeated here. Furthermore, depending on the need, suitable hyaluronic acid synthase mutant genes can be selected to construct engineered bacteria, thereby preparing hyaluronic acid of a specific molecular weight.

[0025] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description

[0026] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which:

[0027] Figure 1 This is a structural prediction model diagram of the hyaluronic acid synthase in Example 1 of the present invention;

[0028] Figure 2 This is a schematic diagram of the key sites for regulating molecular weight synthesis by hyaluronic acid synthase in Example 1 of the present invention;

[0029] Figure 3 This is a graph showing the evaluation results of the hyaluronic acid synthase mutant synthesizing HA molecular weight in Example 4 of the present invention. Detailed Implementation

[0030] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0031] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this invention, unless otherwise stated, "a plurality of" means two or more.

[0032] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0033] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this invention, but do not exclude other aspects.

[0034] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.

[0035] Terms and Definitions

[0036] To facilitate understanding of this invention, certain technical and scientific terms are specifically defined below. Unless explicitly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention pertains. Abbreviations for amino acid residues are the standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.

[0037] In this document, for the purposes of peptide / protein comparison, the term "(substantial) homology" is used to describe or compare the degree of amino acid similarity between two or more peptide / proteins or their designated sequences at optimal alignment and comparison (where appropriate insertions or deletions of amino acids are made). The homology % between two sequences varies with the number of identical positions shared by these sequences at optimal alignment (i.e., homology % = number of identical positions / total number of positions × 100), where optimal alignment is determined taking into account the number of gaps required to achieve optimal alignment of the two sequences and the length of each gap. Sequence comparison and identity percentage determination between two sequences can be performed using mathematical algorithms, as described in the non-limiting examples below.

[0038] In this document, the term "conserved modified amino acid sequence" refers to an amino acid modification that does not significantly affect or alter the biological activity of the polypeptide / protein containing that amino acid sequence. This modification includes amino acid substitution, addition, and deletion. Modifications can be introduced into the mutants of this invention using standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. A conserved amino acid substitution is the replacement of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been identified in the art. These families include amino acids with basic side chains (such as lysine, arginine, and histidine), amino acids with acidic side chains (such as aspartic acid and glutamic acid), amino acids with uncharged polar side chains (such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan), amino acids with nonpolar side chains (such as alanine, valine, leucine, isoleucine, proline, phenylalanine, and methionine), amino acids with β-branched side chains (such as threonine, valine, and isoleucine), and amino acids with aromatic side chains (such as tyrosine, phenylalanine, tryptophan, and histidine).

[0039] This invention proposes a hyaluronic acid synthase mutant, nucleic acid, vector, recombinant cell and engineered bacteria and their applications, which will be described in detail below.

[0040] Hyaluronic acid synthase mutant

[0041] This invention provides a hyaluronic acid synthase mutant. The hyaluronic acid synthase mutant comprises:

[0042] A protein having a mutation at at least one of the amino acid positions 27, 28, 349, and 352 compared to the amino acid sequence shown in SEQ ID NO: 1, and possessing hyaluronic acid synthase activity; or

[0043] A protein that has at least 80% homology to the amino acid sequence of the protein and has hyaluronic acid synthase activity.

[0044] The hyaluronic acid synthase having the amino acid sequence shown in SEQ ID NO: 1 is a wild-type hyaluronic acid synthase. The inventors discovered that by mutating at least one of the amino acid sites at positions 27, 28, 349 and 352, the molecular weight of hyaluronic acid produced by microbial fermentation containing the mutant can be regulated, making it suitable for industrial production applications.

[0045] MRTLKNLITVVAFSIFWVLLIYVNVYLFGAKGSLSIYGFLLIAYLLVKMSLSFFYKPFKGRAGQYKVAAIIPSYNEDAESLLETLKSVQQQTYPLAEIYVVDDGS ADETGIKRIEDYVRDTGDLSSNVIVHRSEKNQGKRHAQAWAFERSDADVFLTVDSDTYIYPDALEELLKTFNDPTVFAATGHLNVRNRQTNLLTRLTDIRYDNAF GVERAAQSVTGNILVCSGPLSVYRREVVVPNIDRYINQTFLGIPVSIGDDRCLTNYATDLGKTVYQSTAKCITDVPDKMSTYLKQQNRWNKSFFRESIISVKKIM NNPFVALWTILEVSMFMMLVYSVVDFFVGNVREFDWLRVLAFLVIIFIVALCRNIHYMLKHPLSFLLSPFYGVLHLFVLQPLKLYSLFTIRNADWGTRKKLL(SEQ ID NO: 1).

[0046] According to embodiments of the present invention, the mutation is a positively charged amino acid or a negatively charged amino acid. Thus, a hyaluronic acid synthase mutant capable of regulating the production of HA of different molecular weights by microbial fermentation is obtained.

[0047] According to an embodiment of the present invention, the positively charged amino acid is selected from arginine, lysine, or histidine. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation is obtained.

[0048] It should be noted that the "increasing (or decreasing) molecular weight of hyaluronic acid (HA) produced by microbial fermentation" described in this invention is compared with the host bacteria expressing wild-type hyaluronic acid synthase with an amino acid sequence as shown in SEQ ID NO: 1.

[0049] According to embodiments of the present invention, the negatively charged amino acid is selected from one of glutamic acid, aspartic acid, anionic serine, or anionic tyrosine; preferably, the anionic serine is selected from phosphoserine, and the anionic tyrosine is selected from phosphotyrosine. Thus, a hyaluronic acid synthase mutant capable of reducing the molecular weight of HA produced by microbial fermentation is obtained.

[0050] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has at least one of the following mutations: L27R, L27K, L27H, F28R, F28K, F28H, F349R, F349K, F349H, L352R, L352K, L352H. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 10-70% is obtained.

[0051] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following mutations at positions 27, 28, 349, or 352: L27R; L27K; F28H; F349H. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 20-30% is obtained.

[0052] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acids 27, 28, 349, or 352: 1) F28R; 2) F28K; 3) F349R; 4) F349K; 5) L352R; 6) L352K; 7) L352H; 8) F28K and F349K. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 20-30% is obtained.

[0053] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acids 27, 28, 349, or 352: 1) L27R and F28R; 2) L27K and F28R; 3) F28R and L352H; 4) L352R and F349H; 5) F28H and L352R; 6) L27H and F28R and F349H; 7) F28R and F349H and L352K. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 30-40% is obtained.

[0054] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acids 27, 28, 349, or 352: 1) L27R and F349R; 2) L27R, F28R, and F349R; 3) L27K, F28R, and F349K; 4) L27R, F28R, F349K, and L352H. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 40-50% is obtained.

[0055] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acids 27, 28, 349, or 352: 1) F28R, F349R, and L352R; 2) F28K, F349R, and L352R; 3) F28H, F349H, and L352K; 4) L27R, F28R, F349R, and L352R; 5) L27R, F28R, F349K, and L352K; 6) L27K, F28K, F349K, and L352H. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 50-60% is obtained.

[0056] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acids 27, 28, 349, or 352: 1) F28R and F349K and L352H; 2) L27K and F28R and F349H and L352R; 3) L27H and F28R and F349H and L352R; 4) L27R and F28R and F349K and L352R; 5) L27K and F28R and F349K and L352H; 6) L27H and F28R and F349K and L352R. Thus, a hyaluronic acid synthase mutant capable of increasing the molecular weight of HA produced by microbial fermentation by 60-70% is obtained.

[0057] Nucleic acid

[0058] This invention provides a nucleic acid. The nucleic acid encodes the aforementioned mutant. According to embodiments of the invention, the nucleic acid can encode a hyaluronic acid synthase mutant capable of regulating microbial fermentation to produce HA of different molecular weights, as described in the first aspect of the invention.

[0059] It should be noted that those skilled in the art will understand that the nucleic acid molecules mentioned herein actually include any one or both of the complementary double strands. For convenience, although only one strand is given in most cases, the complementary strand is also disclosed. Furthermore, the molecular sequences in this invention include DNA or RNA forms; disclosure of one implies that the other is also disclosed.

[0060] carrier

[0061] This invention provides a vector carrying the aforementioned nucleic acid. The vector may include an optional control sequence operatively linked to the nucleic acid molecule. The control sequence is one or more control sequences that direct the expression of the nucleic acid molecule in a host. The resulting vector can effectively express the aforementioned hyaluronic acid synthase mutant.

[0062] When linking the aforementioned nucleic acid molecule to the vector, such as an expression vector, the nucleic acid molecule can be directly or indirectly connected to control elements on the expression vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can be directly derived from the vector itself or be exogenous, i.e., not derived from the vector itself. The nucleic acid molecule and the control elements simply need to be operably linked.

[0063] According to an embodiment of the present invention, the vector is an expression vector.

[0064] According to an embodiment of the present invention, the expression vector is selected from pEC vectors, shuttle vectors, bacteriophages or viral vectors; the pEC vector is preferably a pEC-Ptac vector.

[0065] In this document, the term "operably ligated" refers to ligating a foreign gene to a vector so that the control elements within the vector, such as transcriptional control sequences and translational control sequences, can perform their intended functions of regulating the transcription and translation of the foreign gene. Commonly used vectors include viral vectors, plasmids, bacteriophages, etc. After the expression vector of some specific embodiments of the present invention is introduced into suitable recipient cells, the expression of the aforementioned nucleic acid molecules can be effectively achieved under the mediation of a regulatory system, thereby enabling the large-scale in vitro production of the proteins encoded by the nucleic acid molecules.

[0066] Recombinant cells

[0067] This invention provides a recombinant cell. The recombinant cell expresses the aforementioned hyaluronic acid synthase mutant; or carries the aforementioned nucleic acid or the aforementioned vector. Therefore, according to embodiments of the invention, the recombinant cell can efficiently express the aforementioned hyaluronic acid synthase mutant under suitable conditions, and further, engineered bacteria capable of producing HA of different molecular weights can be obtained, suitable for industrial production applications.

[0068] It should be noted that the "suitable conditions" mentioned in this specification refer to conditions suitable for the expression of the hyaluronic acid synthase mutant described in this invention. Those skilled in the art will readily understand that suitable conditions for the expression of the hyaluronic acid synthase mutant include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. The term "suitable conditions" is not particularly limited, and those skilled in the art can optimize the optimal conditions for the expression of the hyaluronic acid synthase mutant according to the specific environment of their laboratory.

[0069] engineered bacteria

[0070] This invention provides an engineered bacterial strain. The engineered bacterial strain comprises: the aforementioned hyaluronic acid synthase mutant, the aforementioned nucleic acid, or the aforementioned vector. According to embodiments of the invention, the engineered bacterial strain can be used to produce HA of different molecular weights, suitable for industrial production applications.

[0071] According to embodiments of the present invention, the host bacteria of the engineered bacteria are selected from Streptococcus equine, Bacillus subtilis, Escherichia coli, Corynebacterium glutamicum, or Lactococcus lactis; preferably Corynebacterium glutamicum or Escherichia coli. Thus, an engineered bacterium that efficiently expresses the aforementioned hyaluronic acid synthase mutant is obtained.

[0072] method

[0073] This invention provides a method for obtaining hyaluronic acid. The method includes:

[0074] The aforementioned engineered bacteria were fermented to obtain hyaluronic acid.

[0075] According to an embodiment of the present invention, the molecular weight of the hyaluronic acid is 1 kDa to 3000 kDa.

[0076] Those skilled in the art will understand that the features and advantages described above for hyaluronic acid synthase mutants, nucleic acids, recombinant cells or engineered bacteria are also applicable to this method, and will not be repeated here.

[0077] This invention also provides a method for increasing the molecular weight of hyaluronic acid produced by engineered bacteria. The method includes:

[0078] The nucleic acid molecule encoding the aforementioned hyaluronic acid synthase mutant was constructed into an expression vector to obtain a recombinant expression vector;

[0079] The recombinant expression vector was introduced into a host bacterium capable of expressing wild-type hyaluronic acid synthase to obtain engineered bacteria;

[0080] The engineered bacteria were fermented to obtain hyaluronic acid.

[0081] Those skilled in the art will understand that the features and advantages described above for hyaluronic acid synthase mutants, nucleic acids, recombinant cells, or engineered bacteria are also applicable to this method and will not be repeated here. Furthermore, depending on the need, suitable hyaluronic acid synthase mutant genes can be selected to construct engineered bacteria, thereby preparing hyaluronic acid of a specific molecular weight.

[0082] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following mutations at positions 27, 28, 349, or 352: L27R; L27K; F28H; F349H; and the molecular weight of the hyaluronic acid obtained by fermentation of the engineered bacteria is increased by 10-20% compared with the host bacteria expressing wild-type hyaluronic acid synthase.

[0083] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following groups of mutations at amino acids 27, 28, 349, or 352: 1) F28R; 2) F28K; 3) F349R; 4) F349K; 5) L352R; 6) L352K; 7) L352H; 8) F28K and F349K; compared with the host bacteria expressing wild-type hyaluronic acid synthase, the molecular weight of the hyaluronic acid obtained by fermentation by the engineered bacteria is increased by 20-30%.

[0084] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acid positions 27, 28, 349, or 352: 1) L27R and F28R; 2) L27K and F28R; 3) F28R and L352H; 4) L352R and F349H; 5) F28H and L352R; 6) L27H and F28R and F349H; 7) F28R and F349H and L352K; compared with the host bacteria expressing wild-type hyaluronic acid synthase, the molecular weight of hyaluronic acid obtained by fermentation by the engineered bacteria is increased by 30-40%.

[0085] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acid positions 27, 28, 349, or 352: 1) L27R and F349R; 2) L27R, F28R, and F349R; 3) L27K, F28R, and F349K; 4) L27R, F28R, F349K, and L352H; compared with the host bacteria expressing wild-type hyaluronic acid synthase, the molecular weight of the hyaluronic acid obtained by fermentation by the engineered bacteria is increased by 40-50%.

[0086] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acid positions 27, 28, 349, or 352: 1) F28R, F349R, and L352R; 2) F28K, F349R, and L352R; 3) F28H, F349H, and L352K; 4) L27R, F28R, F349R, and L352R; 5) L27R, F28R, F349K, and L352K; 6) L27K, F28K, F349K, and L352H; compared with the host bacteria expressing wild-type hyaluronic acid synthase, the molecular weight of the hyaluronic acid obtained by fermentation by the engineered bacteria is increased by 50-60%.

[0087] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has any one of the following sets of mutations at amino acid positions 27, 28, 349, or 352: 1) F28R and F349K and L352H; 2) L27K and F28R and F349H and L352R; 3) L27H and F28R and F349H and L352R; 4) L27R and F28R and F349K and L352R; 5) L27K and F28R and F349K and L352H; 6) L27H and F28R and F349K and L352R; compared with the host bacteria expressing wild-type hyaluronic acid synthase, the molecular weight of hyaluronic acid obtained by fermentation of the engineered bacteria is increased by 60-70%.

[0088] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0089] Example 1: Design of Hyaluronic Acid Synthesase Mutant

[0090] The structural information of hyaluronic acid synthase was predicted using online open-source software. Based on the analysis of the structure of wild-type hyaluronic acid synthase protein (from Streptococcus equi, amino acid sequence as shown in SEQ ID NO: 1), sequence alignment analysis and structural simulation were performed on the enzyme molecule (pre-simulation results of wild-type hyaluronic acid synthase are shown in [link to software description]). Figure 1 Following this, molecular dynamics simulations were performed to investigate the substrate binding process between the substrate molecule and the enzyme molecule. The inventors proposed a strategy of mutation in the membrane-binding region. Subsequently, through structural analysis, the inventors identified the amino acid sites in the outer region of the hyaluronic acid synthase membrane binding region, including the 27th leucine site, the 28th phenylalanine site, the 349th phenylalanine site, and the 352nd leucine site (e.g., ...). Figure 2 (As shown). To increase the binding ability of the HA chain to the enzyme, a design was developed to mutate any one of the four amino acid sites mentioned above: arginine, lysine, or histidine. Furthermore, combined mutations were performed on these sites.

[0091] Wild-type hyaluronic acid synthase amino acid sequence:

[0092] MRTLKNLITVVAFSIFWVLLIYVNVYLFGAKGSLSIYGFLLIAYLLVKMSLSFFYKPFKGRAGQYKVAAIIPSYNEDAESLLETLKSVQQQTYPLAEIYVVDDGS ADETGIKRIEDYVRDTGDLSSNVIVHRSEKNQGKRHAQAWAFERSDADVFLTVDSDTYIYPDALEELLKTFNDPTVFAATGHLNVRNRQTNLLTRLTDIRYDNAF GVERAAQSVTGNILVCSGPLSVYRREVVVPNIDRYINQTFLGIPVSIGDDRCLTNYATDLGKTVYQSTAKCITDVPDKMSTYLKQQNRWNKSFFRESIISVKKIM NNPFVALWTILEVSMFMMLVYSVVDFFVGNVREFDWLRVLAFLVIIFIVALCRNIHYMLKHPLSFLLSPFYGVLHLFVLQPLKLYSLFTIRNADWGTRKKLL(SEQ ID NO: 1).

[0093] The amino acid site mutations of the designed hyaluronic acid synthase mutants are shown in Table 1.

[0094] Table 1. List of mutation sites in hyaluronic acid synthase mutants

[0095]

[0096]

[0097] Note: In this article, mutation sites are represented using standard substitution notation, such as “N15T”, which means that the N at position 15 from the start N end is replaced by T.

[0098] Example 2: Construction of a hyaluronic acid synthase mutant library

[0099] Different hyaluronic acid synthase mutants from Example 1 were selected to construct recombinant expression vectors.

[0100] Using pEC-XK99E-Ptac-HA plasmid as a template, forward and reverse primers containing the mutation site were designed, and whole-plasmid PCR amplification was performed using PrimeSTAR HSDNA Polymerase (Takara). The recombinant expression vector of the combined mutant was constructed by performing one or more rounds of mutation on a single-point mutant. The introduction of the mutation site also used specific forward and reverse primers containing the mutation site.

[0101] The PCR reaction system is as follows:

[0102] 1 μL pEC-XK99E-Ptac-HA plasmid template (approximately 80 ng / μL);

[0103] 10μL 2×PrimeSTAR HSDNA Polymerase;

[0104] 1.0 μL forward primer (10 μM);

[0105] 1.0 μL reverse primer (10 μM);

[0106] 7μL ddH2O;

[0107] The total reaction volume is 20 μL.

[0108] The PCR reaction conditions are as follows:

[0109] (1) Pre-denaturation at 98℃ for 1 min;

[0110] (2) Denaturation at 98℃ for 30 seconds;

[0111] (3) Anneal (primer Tm-5)℃ for 10s;

[0112] (4) Extend at 72℃ for 7 minutes;

[0113] The above steps (2) to (4) are performed for a total of 30 cycles, and finally extended at 72°C for 10 minutes.

[0114] The recombinant plasmid obtained by PCR amplification was digested with Dpn I enzyme and transformed into E. coli DH5α competent cells. The cells were then plated on LB agar plates containing kanamycin (50 μg / mL) and incubated upside down at 37°C for approximately 12 hours. Single clones were picked for sequencing verification. After successful sequencing verification, the recombinant plasmid pEC-XK99E-Ptac-HAvariant of the hyaluronic acid synthase mutant was extracted and stored at -20°C.

[0115] Example 3: Construction of genetically engineered bacteria containing hyaluronic acid synthase mutants

[0116] The recombinant plasmid (i.e., recombinant expression vector) pEC-XK99E-Ptac-HAvariant prepared in Example 2 was transformed into competent cells (Corynebacterium glutamicum) using the heat shock method. The cells were plated on LB agar plates containing kanamycin (50 μg / mL) and incubated overnight at 37°C. Single colonies were then picked and transferred to LB liquid culture containing 50 μg / mL kanamycin and incubated at 37°C for 12 h before being sent for sequencing.

[0117] The clones that have been verified to be correct by sequencing are stored in a -70°C freezer.

[0118] Thus, genetically engineered bacteria with hyaluronic acid synthase mutants were obtained for subsequent experiments.

[0119] Example 4: Production of HA by shake-flask fermentation of genetically engineered bacteria with hyaluronic acid synthase mutant

[0120] Through site-directed mutagenesis and combined mutagenesis, the inventors obtained a total of 36 hyaluronic acid synthase mutants (see Examples 1 and 2 for details). Through fermentation induction culture, the inventors used the constructed hyaluronic acid synthase mutant genetically engineered bacteria (see Example 3 for details) to produce HA by fermentation and determined the molecular weight of HA obtained thereby.

[0121] The specific methods for HA fermentation production and molecular weight determination are as follows:

[0122] 1. Genetically engineered bacterial cultures containing hyaluronic acid synthase mutants were picked from LB agar plates and transferred to LBG medium containing the appropriate antibiotics. The cultures were incubated overnight at 30°C and 200 rpm. A 5% inoculum was added to a 300 mL Erlenmeyer flask containing 50 mL of fermentation medium, along with the appropriate antibiotics. After incubation at 28°C for 3 hours, IPTG was added to a final concentration of 1 mM to induce expression. The cultures were then incubated at 30°C and 200 rpm for 48 hours, with the pH of the fermentation broth maintained between 6.0 and 8.0. Samples were taken at specified time points to determine the molecular weight of HA in the fermentation samples.

[0123] 2. Method for determining the molecular weight of HA

[0124] (1) Main instruments

[0125] 18-angle light scattering instrument, model Wyatt Technology II modelWH2-06.

[0126] Liquid chromatography column, model TOSOH TSKgel GMPWXL.

[0127] (2) Liquid chromatography conditions

[0128] The mobile phase consisted of 0.2 mol / L sodium chloride and 0.02% Proclin200 preservative. Impurities were removed using a 0.22 μm aqueous filter membrane. The flow rate was 0.5 mL / min, and the column temperature was set to 25 °C.

[0129] The elution time of HA is between 10 and 15 minutes.

[0130] (3) HA sample preparation method

[0131] When the molecular weight of HA is 100kDa, the HA sample is diluted to 1-2 mg / mL; when the molecular weight of HA is 100kDa, the HA sample is diluted to more than 2 mg / mL, and impurities are removed using a 0.22μm filter membrane.

[0132] (4) Calculation of HA molecular weight

[0133] The molecular weight of HA was determined based on the absolute refractive index increment dn / dc = 0.1600 mL / g.

[0134] Specifically, the molecular weight of HA is determined as follows:

[0135] The determination of molecular weight using an 18-degree angle light scattering monitor depends on the following relationship:

[0136] I(θ)scattered∝Mc(dn / dc)^2 where: I(θ)scattered is the intensity of scattered light at any point in the chromatogram, M is the molecular weight of HA, c is the concentration of HA in the sample (measured by RI or UV), dn / dc refers to the absolute refractive index increment, and (dn / dc)^2 represents dn / dc to the power of 2.

[0137] The molecular weight determination results of HA in the hyaluronic acid synthase mutant of this embodiment are shown in Table 2. Figure 3 As shown.

[0138] The above experimental results show that: (1) compared with wild-type hyaluronic acid synthase strains, the hyaluronic acid synthase mutant strains constructed in this invention generally produce higher molecular weight HA; (2) the combined mutant strains of hyaluronic acid synthase in this invention show a significant increase in the molecular weight of HA produced. Specifically, the single-point mutant strains of hyaluronic acid synthase in this invention produce HA with an increase of 5-29%, while the combined mutant strains produce HA with an increase of up to 69%.

[0139] The above results indicate that mutations at amino acid sites affecting the catalytic performance of hyaluronic acid synthase in the membrane-bound outer region can significantly increase the molecular weight of HA produced, and combined mutations at these sites have an even more significant effect on increasing the molecular weight.

[0140] Table 2. Results of HA molecular weight determination in genetically engineered bacteria with hyaluronic acid synthase mutants (Corynebacterium glutamicum as host bacterium).

[0141]

[0142]

[0143] Note: "Mutant ID" indicates the amino acid mutation status of each mutant, and " / " indicates that both mutation types exist simultaneously. For example, the mutant numbered F28R / L352H indicates that the mutant has both F28R and L352H mutation types.

[0144] Example 5: Production of HA by shake-flask fermentation of a hyaluronic acid synthase mutant genetically engineered bacterium using Escherichia coli as the host bacterium.

[0145] Following the methods of Examples 2 and 3, a mutant hyaluronic acid synthase bacterial strain with Escherichia coli as the host bacterium was constructed, and then HA was produced by fermentation. The molecular weight of HA obtained was then determined.

[0146] The specific HA fermentation production method is as follows:

[0147] Genetically engineered bacterial cultures of hyaluronic acid synthase mutants (using *E. coli* as the host bacterium) were picked from LB agar plates and transferred to LBG medium containing the appropriate antibiotics. The cultures were incubated overnight at 37°C and 200 rpm. A 3% inoculum was added to a 300 mL Erlenmeyer flask containing 50 mL of fermentation medium, along with the appropriate antibiotics. After incubation at 37°C for 3 hours, IPTG at a final concentration of 1 mM was added to induce expression. The cultures were then incubated at 30°C and 200 rpm on a shaker for 48 hours, with the pH of the fermentation broth maintained between 6.0 and 8.0. Samples were taken at specified time points to determine the molecular weight of HA in the fermentation samples.

[0148] The specific method for determining the molecular weight of HA is the same as in Example 4.

[0149] The molecular weight determination results of the hyaluronic acid synthase mutant in this example are shown in Table 3.

[0150] Table 3. Results of HA molecular weight determination in genetically engineered bacteria with hyaluronic acid synthase mutants (Escherichia coli as host bacteria).

[0151]

[0152]

[0153] Note: "Mutant ID" indicates the amino acid mutation status of each mutant, and " / " indicates that both mutation types exist simultaneously. For example, the mutant numbered F28R / L352H indicates that the mutant has both F28R and L352H mutation types.

[0154] The above experimental results show that the molecular weight of HA produced by the hyaluronic acid synthase mutant constructed with Escherichia coli as the host bacterium is increased, and the increase effect is basically consistent with that of Corynebacterium glutamicum. This indicates that the hyaluronic acid synthase mutant obtained in this invention can increase the molecular weight of HA in different host bacteria.

[0155] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. A hyaluronic acid synthase mutant, characterized in that, Compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has only one of the following mutations: F28R, F28K, or F28H, and has hyaluronic acid synthase activity.

2. A hyaluronic acid synthase mutant, characterized in that, Compared with the amino acid sequence shown in SEQ ID NO: 1, the hyaluronic acid synthase mutant has only one of the following sets of mutations: 1) L27R and F28R; 2) L27K and F28R; 3) F28K and F349K; 4) F28R and L352H; 5) F28H and L352R; 6) L27R and F28R and F349R; 7) L27H and F28R and F349H; 8) L27K and F28R and F349K; 9) F28R and F349R and L352R; 10) F28R and F349H and L352K; 11) F28K and F349R and L352R; 12) F28R and F349K and L352H; 13) F2 8H and F349H and L352K; 14) L27R and F28R and F349R and L352R; 15) L27K and F28R and F349H and L352R; 16) L27H and F28R and F349H and L352R; 17) L27R and F28R and F349K and L352R; 18) L27R and F28R and F349K and L352K; 19) L27R and F28R and F349K and L352H; 20) L27K and F28K and F349K and L352H; 21) L27K and F28R and F349K and L352H; 22) L27H and F28R and F349K and L352R.

3. A nucleic acid, characterized in that, The nucleic acid encodes the hyaluronic acid synthase mutant of claim 1 or 2.

4. A carrier, characterized in that, The vector carries the nucleic acid as described in claim 3.

5. The carrier according to claim 4, characterized in that, The carrier is an expression carrier.

6. The carrier according to claim 5, characterized in that, The expression vector is selected from pEC vectors, shuttle vectors, bacteriophages, or viral vectors.

7. A recombinant cell, characterized in that, The recombinant cells express the hyaluronic acid synthase mutant of claim 1 or 2; or carry the nucleic acid of claim 3 or the vector of any one of claims 4 to 6.

8. An engineered bacterium, characterized in that, include: The hyaluronic acid synthase mutant of claim 1 or 2, the nucleic acid of claim 3, or the vector of any one of claims 4 to 6.

9. The engineered bacteria according to claim 8, characterized in that, The host bacteria of the engineered bacteria are selected from Streptococcus equine, Bacillus subtilis, Escherichia coli, Corynebacterium glutamicum, or Lactococcus lactis.

10. The engineered bacteria according to claim 8, characterized in that, The host bacteria of the engineered bacteria are selected from Corynebacterium glutamicum or Escherichia coli.

11. A method for obtaining hyaluronic acid, characterized in that, include: Hyaluronic acid is obtained by fermenting the engineered bacteria described in any one of claims 8 to 10.

12. The method according to claim 11, characterized in that, The molecular weight of the hyaluronic acid is 1 kDa to 3000 kDa.

13. A method for increasing the molecular weight of hyaluronic acid produced by engineered bacteria, characterized in that, include: A nucleic acid molecule encoding the hyaluronic acid synthase mutant of claim 1 or 2 is constructed into an expression vector to obtain a recombinant expression vector; The recombinant expression vector was introduced into a host bacterium capable of expressing wild-type hyaluronic acid synthase to obtain engineered bacteria; The engineered bacteria were fermented to obtain hyaluronic acid.

Citation Information

Patent Citations

  • Hyaluronan synthase mutant and application thereof

    CN105838688A

  • High-activity hyaluronidase mutant and application thereof in preparation of oligomeric hyaluronate

    CN116004581A